Details of the Drug

General Information of Drug (ID: DMZ9BMU)

Drug Name
Colistimethate
Synonyms
Colimicina; Colimyscine; Colimycin M; Colistimethale Sodium; Colistimethate sodium; Colistin Sulfomethate; Colistin methanesulfonate sodium salt; Colistin sodium methanesulfonate; Colistin sodium methanesulfonate from bacillus colistinus; Colistin sulfomethate sodium; Colistinemethanesulfonate sodique; Colistrimethate sodium; Colymycin M; Pentasodium colistinmethanesulfonate; Sodium colistimethate; Sodium colistin methanesulfonate; Sodium colistinemethanesulfonate; W 1929; Colistimethate sodium [USAN:INN]; Colistinmethanesulfonic acid, sodium salt; Coly-Mycin M; Coly-Mycin M Parenteral; Coly-mycin injectable
Indication
Disease Entry ICD 11 Status REF
Respiratory tract infection CA45 Approved [1]
Therapeutic Class
Antibiotics
Affected Organisms
Gram-negative bacilli
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski):
4		 Molecular Weight 1749.8
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 39
Hydrogen Bond Donor Count 18
Hydrogen Bond Acceptor Count 33
ADMET Property
Absorption
The drug is very poor absorption from gastrointestinal tract []
Half-life
The concentration or amount of drug in body reduced by one-half in 2 - 3 hours [2]
Chemical Identifiers
Formula
C58H105N16Na5O28S5
IUPAC Name
pentasodium;[2-[17-(1-hydroxyethyl)-22-[[2-[[3-hydroxy-2-[[2-(6-methyloctanoylamino)-4-(sulfonatomethylamino)butanoyl]amino]butanoyl]amino]-4-(sulfonatomethylamino)butanoyl]amino]-5,8-bis(2-methylpropyl)-3,6,9,12,15,18,23-heptaoxo-11,14-bis[2-(sulfonatomethylamino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-2-yl]ethylamino]methanesulfonate
Canonical SMILES
CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC(C(C)O)C(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCNCS(=O)(=O)[O-])CC(C)C)CC(C)C)CCNCS(=O)(=O)[O-])CCNCS(=O)(=O)[O-])C(C)O.[Na+].[Na+].[Na+].[Na+].[Na+]
InChI
InChI=1S/C58H110N16O28S5.5Na/c1-9-35(6)12-10-11-13-46(77)65-38(14-20-59-28-103(88,89)90)53(82)74-48(37(8)76)58(87)70-41(17-23-62-31-106(97,98)99)50(79)68-43-19-25-64-57(86)47(36(7)75)73-54(83)42(18-24-63-32-107(100,101)102)67-49(78)39(15-21-60-29-104(91,92)93)69-55(84)44(26-33(2)3)72-56(85)45(27-34(4)5)71-52(81)40(66-51(43)80)16-22-61-30-105(94,95)96;;;;;/h33-45,47-48,59-63,75-76H,9-32H2,1-8H3,(H,64,86)(H,65,77)(H,66,80)(H,67,78)(H,68,79)(H,69,84)(H,70,87)(H,71,81)(H,72,85)(H,73,83)(H,74,82)(H,88,89,90)(H,91,92,93)(H,94,95,96)(H,97,98,99)(H,100,101,102);;;;;/q;5*+1/p-5
InChIKey
IQWHCHZFYPIVRV-UHFFFAOYSA-I
Cross-matching ID
PubChem CID
216258
CAS Number
8068-28-8
UNII
DL2R53P963
DrugBank ID
DB01111
TTD ID
D0Q3BV
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial Dihydropteroate synthetase (Bact folP) TT4ILYC DHPS_ECOLI Binder [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Colistimethate (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Decreased renal excretion of Colistimethate caused by Remdesivir mediated nephrotoxicity. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [4]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Colistimethate and Inotersen. Amyloidosis [5D00] [5]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Colistimethate and Iodipamide. Cholelithiasis [DC11] [6]
Atracurium DM42HXN Major Additive neuromuscular blocking effects by the combination of Colistimethate and Atracurium. Corneal disease [9A76-9A78] [7]
Mivacurium DM473VD Major Additive neuromuscular blocking effects by the combination of Colistimethate and Mivacurium. Corneal disease [9A76-9A78] [7]
Pancuronium DMB0VY8 Major Additive neuromuscular blocking effects by the combination of Colistimethate and Pancuronium. Corneal disease [9A76-9A78] [7]
Tubocurarine DMBZIVP Major Additive neuromuscular blocking effects by the combination of Colistimethate and Tubocurarine. Corneal disease [9A76-9A78] [7]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Colistimethate and Exjade. Mineral absorption/transport disorder [5C64] [8]
Everolimus DM8X2EH Major Increased risk of nephrotoxicity by the combination of Colistimethate and Everolimus. Renal cell carcinoma [2C90] [9]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Colistimethate and Temsirolimus. Renal cell carcinoma [2C90] [9]
Pipecuronium DM5F84A Major Additive neuromuscular blocking effects by the combination of Colistimethate and Pipecuronium. Tonus and reflex abnormality [MB47] [7]
Doxacurium DMKE7L9 Major Additive neuromuscular blocking effects by the combination of Colistimethate and Doxacurium. Tonus and reflex abnormality [MB47] [7]
Vecuronium DMP0UK2 Major Additive neuromuscular blocking effects by the combination of Colistimethate and Vecuronium. Tonus and reflex abnormality [MB47] [7]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Colistimethate and Olsalazine. Ulcerative colitis [DD71] [10]
⏷ Show the Full List of 14 DDI Information of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 064216.
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7.
4 Cerner Multum, Inc. "Australian Product Information.".
5 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
6 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
7 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
8 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
9 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
10 Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]